Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

References

• Ogden CL Carroll MD Kit BK Flegal KM Prevalence of obesity in the United States, 2009–2010 NCHS Data Brief 2012 82 1 8
   Google Scholar
• Finkelstein EA Khavjou OA Thompson H Obesity and severe obesity forecasts through 2030 Am J Prev Med 2012 42 6 563 570 22608371
   PubMed Web of Science ®Google Scholar
• Finkelstein EA Trogdon JG Cohen JW Dietz W Annual medical spending attributable to obesity: payer- and service-specific estimates Health Aff (Millwood) 2009 28 5w822 5w831
   Web of Science ®Google Scholar
• National Heart, Lung and Blood Institute (NHLBI) Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report Report number 98-4083 Bethesda, MD NHLBI 1998 Available from: http://www.ncbi.nlm.nih.gov/books/NBK2003/ Accessed May 15, 2014
   Google Scholar
• Berrington de Gonzalez A Hartge P Cerhan JR Body-mass index and mortality among 1.46 million white adults N Engl J Med 2010 363 23 2211 2219 21121834
   PubMed Web of Science ®Google Scholar
• George M Rajaram M Shanmugam E New and emerging drug molecules against obesity J Cardiovasc Pharmacol Ther 2014 19 1 65 76 24064009
   PubMed Web of Science ®Google Scholar
• Weight-Control Information Network (WIN) Prescription Medications for the Treatment of Obesity Bethesda, MD National Institutes of Health 2009 Available from: http://www.win.niddk.nih.gov/publications/PDFs/Prescription_Medications.pdf Accessed May 1, 2014
   Google Scholar
• Rodgers RJ Tschöp MH Wilding JP Anti-obesity drugs: past, present and future Dis Model Mech 2012 5 5 621 626 22915024
   PubMed Web of Science ®Google Scholar
• Ling H Lenz TL Burns TL Hilleman DE Reducing the risk of obesity: defining the role of weight loss drugs Pharmacotherapy 2013 33 12 1308 1321 23712541
   PubMed Web of Science ®Google Scholar
• Klonoff DC Greenway F Drugs in the pipeline for the obesity market J Diabetes Sci Technol 2008 2 5 913 918 19885278
   PubMedGoogle Scholar
• Kaplan LM Pharmacological therapies for obesity Gastroenterol Clin North Am 2005 34 1 91 104 15823441
   PubMed Web of Science ®Google Scholar
• Halford JC Boyland EJ Blundell JE Kirkham TC Harrold JA Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 2010 6 5 255 269 20234354
   PubMed Web of Science ®Google Scholar
• Nathan PJ O’Neill BV Napolitano A Bullmore ET Neuropsychiatric adverse effects of centrally acting antiobesity drugs CNS Neurosci Ther 2011 17 5 490 505 21951371
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674 21197148
   PubMedGoogle Scholar
• Witkamp RF Current and future drug targets in weight management Pharm Res 2011 28 8 1792 1818 21181547
   PubMed Web of Science ®Google Scholar
• Bray GA Ryan DH Drug treatment of obesity Psychiatr Clin N Am 2011 34 4 871 880
   Web of Science ®Google Scholar
• Hiatt WR Thomas A Goldfine AB What cost weight loss? Circulation 2012 125 9 1171 1177 22392864
   PubMed Web of Science ®Google Scholar
• Carter R Mouralidarane A Ray S Soeda J Oben J Recent advancements in drug treatment of obesity Clin Med 2012 12 5 456 460 23101148
   PubMed Web of Science ®Google Scholar
• Derosa G Maffioli P Anti-obesity drugs: a review about their effects and their safety Expert Opin Drug Saf 2012 11 3 459 471 22439841
   PubMed Web of Science ®Google Scholar
• Chugh PK Sharma S Recent advances in the pathophysiology and pharmacological treatment of obesity J Clin Pharm Ther 2012 37 5 525 535 22462645
   PubMed Web of Science ®Google Scholar
• Heal DJ Gosden J Smith SL What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012 63 1 132 146 22313529
   PubMed Web of Science ®Google Scholar
• Ryan DH Bray GA Pharmacologic treatment options for obesity: what is old is new again Curr Hypertens Rep 2013 15 3 182 189 23625271
   PubMed Web of Science ®Google Scholar
• Boulghassoul-Pietrzykowska N Franceschelli J Still C New medications for obesity management: changing the landscape of obesity treatment Curr Opin Endocrinol Diabetes Obes 2013 20 5 407 411 23974768
   PubMedGoogle Scholar
• Heal DJ Gosden J Smith SL A review of late-stage CNS drug candidates for the treatment of obesity Int J Obes (Lond) 2013 37 1 107 117 22410963
   PubMed Web of Science ®Google Scholar
• Howland RH Therapies for obesity and medication-associated weight gain J Psychosoc Nurs Ment Health Serv 2013 51 5 13 16
   Web of Science ®Google Scholar
• Rueda-Clausen CF Padwal RS Sharma AM New pharmacological approaches for obesity management Nat Rev Endocrinol 2013 9 8 467 478 23752772
   PubMed Web of Science ®Google Scholar
• Clapper JR Athanacio J Wittmer C Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models Eur J Pharmacol 2013 698 1–3 292 298 23178527
   PubMed Web of Science ®Google Scholar
• Greenway FL Whitehouse MJ Guttadauria M Rational design of a combination medication for the treatment of obesity Obesity (Silver Spring) 2009 17 1 30 39 18997675
   PubMed Web of Science ®Google Scholar
• Lee MW Fujioka K Naltrexone for the treatment of obesity: review and update Expert Opin Pharmacother 2009 10 11 1841 1845 19537999
   PubMed Web of Science ®Google Scholar
• Plodkowski RA Nguyen Q Sundaram U Nguyen L Chau DL St Jeor S Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity Expert Opin Pharmacother 2009 10 6 1069 1081 19364254
   PubMed Web of Science ®Google Scholar
• Greenway FL Dunayevich E Tollefson G NB-201 Study Group Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo J Clin Endocrinol Metab 2009 94 12 4898 4906 19846734
   PubMed Web of Science ®Google Scholar
• Wilcox CS Oskooilar N Erickson JS An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects Addict Behav 2010 35 3 229 234 19926400
   PubMed Web of Science ®Google Scholar
• Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR Drugs R D 2010 10 1 25 32 20509712
   PubMedGoogle Scholar
• Citrome L Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? Int J Clin Pract 2010 64 11 1462 1465 20846190
   PubMed Web of Science ®Google Scholar
• Astrup A Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010 376 9741 567 568 20673996
   PubMed Web of Science ®Google Scholar
• Greenway FL Fujioka K Plodkowski RA COR-I Study Group Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 20673995
   PubMed Web of Science ®Google Scholar
• New obesity pill: new hopes, old fears Lancet 2010 376 9758 2042
   Web of Science ®Google Scholar
• Mercer SL ACS chemical neuroscience molecule spotlight on contrave ACS Chem Neurosci 2011 2 9 484 486 22860172
   PubMed Web of Science ®Google Scholar
• Katsiki N Hatzitolios AI Mikhailidis DP Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’? Ann Med 2011 43 4 249 258 21254901
   PubMed Web of Science ®Google Scholar
• Ornellas T Chavez B Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults P T 2011 36 5 255 262 21785538
   PubMedGoogle Scholar
• Halpern B Faria AM Halpern A Bupropion/naltrexone fixed-dose combination for the treatment of obesity Drugs Today (Barc) 2011 47 8 575 581 21850280
   PubMed Web of Science ®Google Scholar
• Billes SK Greenway FL Combination therapy with naltrexone and bupropion for obesity Expert Opin Pharmacother 2011 12 11 1813 1826 21689063
   PubMed Web of Science ®Google Scholar
• Plutzky J Chilton R Still C Burns C Kim D Dunayevich E Weight loss, blood pressure, pulse and circadian patterns with naltrexone sustained-release/Bupropion sustained-release combination therapy for obesity J Am Coll Cardiol 2011 57 14s1 E517
   Web of Science ®Google Scholar
• Reece AS Hypothalamic opioid-melanocortin appetitive balance and addictive craving Med Hypotheses 2011 76 1 132 137 20926200
   PubMed Web of Science ®Google Scholar
• Makowski CT Gwinn KM Hurren KM Naltrexone/bupropion: an investigational combination for weight loss and maintenance Obes Facts 2011 4 6 489 494 22249001
   PubMed Web of Science ®Google Scholar
• Wadden TA Foreyt JP Foster GD Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial Obesity (Silver Spring) 2011 19 1 110 120 20559296
   PubMed Web of Science ®Google Scholar
• Smith SR Fujioka K Gupta AK Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity Diabetes Obes Metab 2013 15 9 863 866 23489381
   PubMed Web of Science ®Google Scholar
• Apovian CM Aronne L Rubino D COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 2013 21 5 935 943 23408728
   PubMed Web of Science ®Google Scholar
• McElroy SL Guerdjikova AI Kim DD Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study Prim Care Companion CNS Disord 2013 15 3 pii:PCC.12m01494
   Google Scholar
• Wang GJ Tomasi D Volkow ND Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues Int J Obes (Lond) 2014 38 5 682 688 23924756
   PubMed Web of Science ®Google Scholar
• Woods SC D’Alessio DA Central control of body weight and appetite J Clin Endocrinol Metab 2008 93 11 Suppl 1 S37 S50 18987269
   PubMed Web of Science ®Google Scholar
• Gadde KM Parker CB Maner LG Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women Obes Res 2001 9 9 544 551 11557835
   PubMedGoogle Scholar
• Anderson JW Greenway FL Fujioka K Gadde KM McKenney J O’Neil PM Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial Obes Res 2002 10 7 633 642 12105285
   PubMedGoogle Scholar
• Lobmaier PP Kunøe N Gossop M Waal H Naltrexone depot formulations for opioid and alcohol dependence: a systematic review CNS Neurosci Ther 2011 17 6 629 636 21554565
   PubMed Web of Science ®Google Scholar
• Naltrexone hydrochloride tablets USP 50 mg [prescribing information] St Louis, MO Mallinckrodt Available from: http://www.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=1943 Accessed August 1, 2014
   Google Scholar
• Holtzman SG Suppression of appetitive behavior in the rat by naloxone: lack of effect of prior morphine dependence Life Sci 1979 24 3 219 226 570626
   PubMed Web of Science ®Google Scholar
• Yeomans MR Gray RW Opioid peptides and the control of human ingestive behaviour Neurosci Biobehav Rev 2002 26 6 713 728 12479844
   PubMed Web of Science ®Google Scholar
• Fantino M Hosotte J Apfelbaum M An opioid antagonist, naltrexone, reduces preference for sucrose in humans Am J Physiol 1986 251 1 Pt 2 R91 R96 3728712
   PubMed Web of Science ®Google Scholar
• Spiegel TA Stunkard AJ Shrager EE O’Brien CP Morrison MF Stellar E Effect of naltrexone on food intake, hunger, and satiety in obese men Physiol Behav 1987 40 2 135 141 3628520
   PubMed Web of Science ®Google Scholar
• Atkinson RL Berke LK Drake CR Bibbs ML Williams FL Kaiser DL Effects of long-term therapy with naltrexone on body weight in obesity Clin Pharmacol Ther 1985 38 4 419 422 4042525
   PubMed Web of Science ®Google Scholar
• Maggio CA Presta E Bracco EF Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men Brain Res Bull 1985 14 6 657 661 3896411
   PubMed Web of Science ®Google Scholar
• Malcolm R O’Neil PM Sexauer JD Riddle FE Currey HS Counts C A controlled trial of naltrexone in obese humans Int J Obes 1985 9 5 347 353 3908352
   PubMed Web of Science ®Google Scholar
• de Zwaan M Mitchell JE Opiate antagonists and eating behavior in humans: a review J Clin Pharmacol 1992 32 12 1060 1072 1487543
   PubMed Web of Science ®Google Scholar
• Mitchell JE Morley JE Levine AS Hatsukami D Gannon M Pfohl D High-dose naltrexone therapy and dietary counseling for obesity Biol Psychiatry 1987 22 1 35 42 3790639
   PubMed Web of Science ®Google Scholar
• Korner J Leibel RL To eat or not to eat – how the gut talks to the brain N Engl J Med 2003 349 10 926 928 12954739
   PubMed Web of Science ®Google Scholar
• Orexigen Therapeutics, Inc Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) ClinicalTrials.gov [website on the Internet] Bethseda, MD US National Library of Medicine 2012 [updated May 20, 2014]. Available from: http://clinicaltrials.gov/show/NCT01601704. NLM identifier: NCT01601704 Accessed June 6, 2014
   Google Scholar